Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Cash from Discontinued Operations (2020 - 2021)

Historic Cash from Discontinued Operations for Agios Pharmaceuticals (AGIO) over the last 2 years, with Q4 2021 value amounting to -$4.1 million.

  • Agios Pharmaceuticals' Cash from Discontinued Operations fell 33547.65% to -$4.1 million in Q4 2021 from the same period last year, while for Sep 2022 it was -$4.1 million, marking a year-over-year increase of 9530.61%. This contributed to the annual value of -$93.2 million for FY2021, which is 9915.41% down from last year.
  • Per Agios Pharmaceuticals' latest filing, its Cash from Discontinued Operations stood at -$4.1 million for Q4 2021, which was down 33547.65% from -$10.3 million recorded in Q3 2021.
  • Agios Pharmaceuticals' 5-year Cash from Discontinued Operations high stood at $1.7 million for Q4 2020, and its period low was -$48.3 million during Q2 2021.